2026年第一季度,全球制药巨头的业绩版图再度刷新。 一边,礼来凭借替尔泊肽的强势爆发点燃增长引擎,诺和诺德用司美格鲁肽四条管线合计突破528亿丹麦克朗全线扩张;另一边,默沙东在K药顶住专利竞争压力的同时开始培育新一代增长点,赛诺菲以Dupixent续写自免领域的统治传奇。 在多款核心产品的合力带动下,这些跨国药企在2026年强势开局。 有券商医药行业分析师对21世纪经济报道记者表示,当前...
Source Link2026年第一季度,全球制药巨头的业绩版图再度刷新。 一边,礼来凭借替尔泊肽的强势爆发点燃增长引擎,诺和诺德用司美格鲁肽四条管线合计突破528亿丹麦克朗全线扩张;另一边,默沙东在K药顶住专利竞争压力的同时开始培育新一代增长点,赛诺菲以Dupixent续写自免领域的统治传奇。 在多款核心产品的合力带动下,这些跨国药企在2026年强势开局。 有券商医药行业分析师对21世纪经济报道记者表示,当前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.